Table 2
From the following article
Nature Biotechnology 26, 11 - 12 (2008)
doi:10.1038/nbt0108-11
Table 2. New product approval
| Product | Details |
|---|---|
BH | |
| Mircera (methoxy polyethylene glycol-epoetin beta), Roche (Basel). | The US Food and Drug Administration approved the erythropoiesis-stimulating drug Mircera for treating anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis. However, the drug has been blocked from the US market by litigation from Amgen, of Thousand Oaks, California, which sued for patent infringement on its epoetin patents. |